Gastritis, Chronic, Erosive

Gastritis, Chronic, Erosive

National Organization for Rare Disorders, Inc.

Important

It is possible that the main title of the report Gastritis, Chronic, Erosive is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.

Synonyms

  • Idiopathic Chronic, Erosive Gastritis
  • Varioliform Gastritis

Disorder Subdivisions

  • None

General Discussion

Chronic, Erosive Gastritis is characterized by many inflamed lesions in the mucous lining of the stomach. It may be a transitory or a chronic condition lasting for years.

Symptoms

Chronic, Erosive Gastritis is an inflammation of the stomach characterized by multiple lesions in the mucous lining causing ulcer-like symptoms. These symptoms may include a burning and heavy feeling in the pit of the stomach, mild nausea, vomiting, loss of appetite and weakness. In severe cases there can be bleeding of the stomach which may result in anemia. Some people with this disorder, especially chronic aspirin users, may show no apparent symptoms until the disease has advanced. An accurate diagnosis can be made by physician's visual inspection of the stomach using a gastroscope.

Causes

The exact cause of Chronic, Erosive Gastritis is unknown. It may be the result of an infection, over indulgence of alcohol, or persistent use of aspirin or non-steroidal anti-inflammatory medications such as ibuprofen. Stress tends to make symptoms worse. Crohn's disease and Sarcoidosis have been known to be factors in some cases of Chronic, Erosive Gastritis, while some cases have no apparent cause at all.

Affected Populations

Chronic, Erosive Gastritis usually occurs during middle age and is more common in males than females. Alcoholics and chronic aspirin or ibuprofen users (e.g. people with arthritis) are more susceptible to this disorder.

Standard Therapies

Because Chronic, Erosive Gastritis may cause symptoms similar to other gastrointestinal disorders, a full medical history must be known before an effective treatment can be determined. Most cases are usually treated with acid neutralizing medications (antacids) and H2 blocker drugs such as Zantac (ranitidine) or Tagamet (cimetidine). Dietary changes and avoiding the irritating causes such as stomach irritating drugs or stressful situations are also helpful in eliminating the symptoms of Chronic, Erosive Gastritis.



The prostaglandin E1 analog drug, Cytotec (misoprostol) has proven to be an effective preventative medication for gastric lesions associated with high-dose aspirin or ibuprofen therapy. This drug is effective in healing the gastric mucosal lesions without altering the therapeutic benefits of the non-steroidal anti-inflammatory drugs given to arthritis patients. Misoprostol can have severe effects on a developing fetus and must be administered with extreme caution. Other treatment is symptomatic and supportive.

Investigational Therapies

At the present time, a study is being conducted on the effectiveness of the drug bismuthsubsalicylate as a treatment for Chronic, Erosive Gastritis. More research must be conducted to determine long-term safety and effectiveness of this drug.



Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.



For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:



Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov



For information about clinical trials sponsored by private sources, contact:

www.centerwatch.com

References

TEXTBOOKS

Internal Medicine, 2nd Ed.: Jay H. Stein, ed-in-chief; Little, Brown and Co., 1987. Pp. 110.



The Merck Manual, 15th Ed.: Robert Berkow, M.D. ed-in-chief; Merck, Sharp & Dohme Laboratories., 1987. Pp. 736.



JOURNAL ARTICLES

Treatment of Chronic Erosive Gastritis with Prednisolone. M. Farthing et al.; Gut (Sept 1981; 22(9)). Pp. 759-62.



Mechanisms of Non-Steroidal Anti-Inflammatory Drug-Induced Gastric Damage. R. Schoen et al.; Am J Med (Apr 1989; 86(4)). Pp. 449-558.



Neoplasia in Chronic Erosive (Valioliform) Gastritis. M. Cappell et al.; Dig Dis Sci (Aug 1988; 33(8)). Pp. 1035-39.



Misoprostol Heals Gastroduodenal Injury in Patients with Rheumatoid Arthritis Receiving Aspirin. S. Roth et al.; Arch Intern Med (Apr 1989; 149(4)). Pp. 775-79.



Prostaglandin E1 Analogue Therapy in the Treatment of Refractory Gastric Ulcer in an Elderly Patient. E. Ramsey et al.; Arch Intern Med (Oct 1988; 148(10)). Pp. 2275-76.



Chronic Erosive Gastritis: A Clinical Study. C. Gallagher et al.; Am J Gastroenterol (Apr 1987; 82(4)). Pp. 302-06.



Chronic Erosive Gastritis - A Recently Recognized Disorder. G. Elta et al.; Dig Dis Sci (Jan 1983; 28(1)). Pp. 7-12.



FROM THE INTERNET

eMedicine - Gastritis, Acute : Article by Mohammad Wehbi, MD



http://www.emedicine.com/MED/topic850.htm

Resources

Crohn's and Colitis Foundation of America

386 Park Avenue South

17th Floor

New York, NY 10016-7374

USA

Tel: (212)685-3440

Fax: (212)779-4098

Tel: (800)932-2423

Email: info@ccfa.org

Internet: http://www.ccfa.org



Digestive Disease National Coalition

507 Capitol Court, NE

Suite 200

Washington, DC 20002

Tel: (202)544-7497

Fax: (202)546-7105

Email: ddnc@hmcw.org

Internet: http://www.ddnc.org



NIH/National Institute of Diabetes, Digestive & Kidney Diseases

Office of Communications & Public Liaison

Bldg 31, Rm 9A06

31 Center Drive, MSC 2560

Bethesda, MD 20892-2560

Tel: (301)496-3583

Email: NDDIC@info.niddk.nih.gov

Internet: http://www2.niddk.nih.gov/



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/



CORE

3 St. Andrews Place

London, NW1 4LB

United Kingdom

Tel: 02074860341

Fax: 02072242012

Email: info@corecharity.org.uk

Internet: http://www.corecharity.org.uk



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use . How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.